#liver cancer

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

Karen Hoyt promised her grandkids she would win a gold medal in the World Transplant Games. She wasn’t going to let HCC stand in her way.

Researchers compared health outcomes among people with HIV, including those with and without hepatitis C.

Some of the most common and deadly cancers receive little attention and resources.

An analysis conducted in Taiwan analyzed health outcomes over more than a decade.

Researchers analyzed health data regarding modern hep C treatments specific to New South Wales.

Researchers reached this conclusion after reviewing data on more than 30,000 people.

European and U.S. guidelines recommend that all those with cirrhosis undergo biannual screening for liver cancer.

Phase III study misses statistical threshold, but the immunotherapy appears to show some benefit.

Even positive breaking news looks different to people who know the reality of a hard-to-treat cancer.

Study in China sees an association with several cancer types, especially gastrointestinal malignancies.

Keytruda showed modest benefits for people with this difficult-to-treat cancer, and combining Opdivo with Yervoy improved outcomes.

HIV-positive individuals are also diagnosed with cancer at later stages than those without the virus.

Responding to the increasing incidence of liver cancer in the United States

A new systematic review and meta-analysis indicates that hepatitis C is most notably also associated with B-cell non–Hodgkin lymphoma.

There are now five targeted therapies for the most common type of liver cancer.